Silex Systems : Webcast of 2014 Annual General Meeting

Silex Systems Limited

A.C.N. 003 372 067

Level 8, Suite 8.03

56 Clarence Street

Sydney NSW 2000 Australia

PO Box 364

Sydney NSW 2001

Tel: + 61 2 9704 8888

Fax: +61 2 9279 1051 www.silex.com.au

Speaker: Dr Michael Goldsworthy, CEO and Managing Director

Live date: Tuesday, 18th November 2014 9.30am AEDT

Access this webcast at: http://www.openbriefing.com/OB/1639.aspx

Further information on the Company's activities can be found on the Silex website:

www.silex.com.auor by contacting the persons listed below.

1 | P a g e

About Silex

In June 2014, a major strategic review of Silex Systems Limited (ASX: SLX) (OTCQX: SILXY) resulted in a significant restructure of the Company. Under the restructure, the Board determined to refocus efforts on the Company's primary economic asset, and to significantly reduce cash burn beyond FY 2015.

This strategic review would allow Silex to support uranium enrichment technology licensee, GE- Hitachi Global Laser Enrichment with their efforts to bring the SILEX Technology to market. Should this be successfully achieved, Silex could earn attractive royalty revenues, under a technology commercialisation and license agreement, signed originally in 2006.

Under the restructure, it was also announced that the transitions to market for subsidiaries Solar Systems and Translucent would be accelerated, and that operations at ChronoLogic would cease, all during FY2015.

For more detailed information on Silex Systems Limited, please visit www.silex.com.au

Silex Systems is a research and development Company whose assets are its proprietary rights in various technologies, including, but not limited to, the SILEX technology, Solar Systems technology and business, Translucent technology and ChronoLogic technology. Several of the Company's technologies are in the development stage and have not been commercially deployed, and therefore are high-risk. Accordingly, the statements in this announcement regarding the future of the Company's technologies and commercial prospects are forward looking and actual results could be materially different from those expressed or implied by such forward looking statements as a result of various risk factors.
Some risk factors that could affect future results and commercial prospects include, but are not limited to: results from the SILEX uranium enrichment commercialisation program; the demand for enriched uranium; the risks associated with the development of Solar Systems technology and related marketing activities; the outcomes of the Company's interests in the development of various semiconductor, photonics, instrumentation and alternative energy technologies; the time taken to develop various technologies; the development of competing technologies; the potential for third party claims against the Company's ownership of Intellectual Property associated with its numerous technologies; the potential impact of government regulations or policies; and the outcomes of various commercialisation strategies undertaken by the Company.

2 | P a g e

distributed by